Kaja Kostyrko

Aug 5, 2024 | nature.com | Venu Thatikonda |Kaja Kostyrko |Donát Alpár |Daniel Gerlach |Melanie Hinkel |Jessica M Molkentine | +5 more

AbstractCombination approaches are needed to strengthen and extend the clinical response to KRASG12C inhibitors (KRASG12Ci). Here, we assessed the antitumor responses of KRASG12C mutant lung and colorectal cancer models to combination treatment with a SOS1 inhibitor (SOS1i), BI-3406, plus the KRASG12C inhibitor, adagrasib.

Jul 5, 2023 | nature.com | Kaja Kostyrko |Stanley Leung |Peter Jackson

AbstractKRAS is a frequent driver in lung cancer. To identify KRAS-specific vulnerabilities in lung cancer, we performed RNAi screens in primary spheroids derived from a Kras mutant mouse lung cancer model and discovered an epigenetic regulator Ubiquitin-like containing PHD and RING finger domains 1 (UHRF1). In human lung cancer models UHRF1 knock-out selectively impaired growth and induced apoptosis only in KRAS mutant cells.